Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 113-125 , February 2006

Dendritic Cell Immunotherapy for the Treatment of Neoplastic Disease

  • William K. Decker

      Affiliations

    • Corresponding Author InformationCorrespondence and reprint requests: William K. Decker, PhD, Department of Blood and Marrow Transplantation, University of Texas M.D. Anderson Cancer Center, Box 65, 1515 Holcombe Blvd., Houston, TX 77030
    • ,
  • Dongxia Xing
    • ,
  • Elizabeth J. Shpall

Received 25 June 2005 ,Accepted 7 September 2005.

References 

  1. Mukherji B , Chakraborty NG , Yamasaki S , et al.   Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells . Proc Natl Acad Sci U S A . 1995;92:8078–8082
  2. Colonna M , Tinchieri G , Liu YJ . Plasmacytoid dendritic cells in immunity . Nat Immunol . 2004;5:1219–1226
  3. McKenna K , Beignon AS , Bhardwaj N . Plasmacytoid dendritic cells (linking innate and adaptive immunity) . J Virol . 2005;79:17–27
  4. Banchereau J , Palucka AK . Dendritic cells as therapeutic vaccines against cancer . Nat Rev Immunol . 2005;5:296–306
  5. Siegal FP , Kadowaki N , Shodell M , et al.   The nature of the principle type 1 interferon-producing cells in human blood . Science . 1999;284:1835–1837
  6. Iwasaki A , Medzhitov R . Toll-like receptor control of the adaptive immune responses . Nat Immunol . 2004;5:987–995
  7. Coccia EM , Severa E , Giancomini D , et al.   Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells . Eur J Immunol . 2004;34:796–805
  8. Banchereau J , Paczesny S , Blanco P , et al.   Dendritic cells (controllers of the immune system and a new promise for immunotherapy) . Ann N Y Acad Sci . 2003;987:180–187
  9. Hartgers FC , Figdor CG , Adema GJ . Towards a molecular understanding of dendritic cell immunobiology . Immunol Today . 2000;21:542–545
  10. Krug A , Towarowski S , Bristch S , et al.   Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12 . Eur J Immunol . 2001;31:3026–3037
  11. Chehimi J , Starr SE , Kawashima H , et al.   Dendritic cells and IFN-α-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood . Immunology . 1989;68:488–490
  12. O’Doherty U , Peng M , Gezelter S , et al.   Human blood contains two subsets of dendritic cells, one immunologically mature and the other immature . Immunology . 1994;82:487–493
  13. Grouard G , Rissoan MC , Filgueira L , et al.   The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand . J Exp Med . 1997;185:1101–1111
  14. Fiebiger E , Meraner P , Weber E , et al.   Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells . J Exp Med . 2001;193:881–892
  15. Ueda Y , Haigihara M , Okamoto A , et al.   Frequencies of dendritic cells (myeloid DC and plasmacytoid DC) and their ratio reduced in pregnant women (comparison with umbilical cord blood and normal healthy adults) . Hum Immunol . 2003;64:1144–1151
  16. Kadowaki N , Antoneko S , Lau JYN , Liu YJ . Natural interferon-α/β-producing cells link innate and adaptive immunity . J Exp Med . 2000;192:219–226
  17. Fitzgerald-Bocarsly P , Feldman PM , Mendelsohn M , Curl S , Lopez C . Human mononuclear cells which produce interferon-alpha during NK[HSV-FS] assays are HLA-DR positive cells distinct from cytolytic natural killer effectors . J Leukoc Biol . 1988;43:323–334
  18. Cella M , Jarrossay D , Facchetti F , et al.   Plasmacytoid monocytes migrate to inflamed lymph nodes and produce high levels of type I IFN . Nat Med . 1999;5:919–923
  19. Cella M , Facchetti F , Lanzavecchia A , Colonna M . Plasmacytoid dendritic cells activated by influenza virus and CD40L drive a potent TH1 polarization . Nat Immunol . 2000;1:305–310
  20. Lore K , Metts MR , Benchley JM , et al.   Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses . J Immunol . 2003;171:4320–4328
  21. Moseman EA , Liang X , Dawson AJ , et al.   Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells . J Immunol . 2004;173:4433–4442
  22. Martin P , Del Hoyo GM , Anjuere F , et al.   Characterization of a new subpopulation of mouse CD8α+B220+ dendritic cells endowed with type 1 interferon production capacity and tolerogenic potential . Blood . 2002;100:383–390
  23. Bilsborough J , Viney JL . Getting to the guts of immune regulation . Immunology . 2002;106:139–143
  24. Kuwana M , Kaburaki J , Wright TM , Kawakami Y , Ikeda Y . Induction of antigen-specific human CD4+ T cell anergy by peripheral blood DC2 precursors . Eur J Immunol . 2001;31:2547–2557
  25. Sallusto F , Lanzavecchia A . Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha . J Exp Med . 1994;179:1109–1118
  26. Romani N , Reider D , Heuer M , et al.   Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability . J Immunol Methods . 1996;196:137–151
  27. Heiser A , Dahm P , Yancey DR , et al.   Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro . J Immunol . 2000;164:5508–5514
  28. Caux C , Dezutter-Dambuyant C , Schmidt D , Banchereau J . GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells . Nature . 1992;360:258–261
  29. Caux C , Massacrier C , Dezutter-Dambuyant C , et al.   Human dendritic Langerhans cells generated in vitro from CD34+ progenitors can prime naive CD4+ T cells and process soluble antigen . J Immunol . 1995;155:5427–5435
  30. Banchereau J , Palucka AK , Dhodapkar M , et al.   Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine . Cancer Res . 2001;61:6451–6458
  31. Mackensen A , Herbst B , Chen JL , et al.   Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells . Int J Cancer . 2000;86:385–392
  32. Di Nicola M , Carlo-Stella C , Mortarini R , et al.   Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-transduced, CD34+-derived dendritic cell vaccination (a phase I trial in metastatic melanoma) . Clin Cancer Res . 2004;10:5381–5390
  33. Peters JH , Xu H , Ruppert J , et al.   Signals required for differentiating dendritic cells from human monocytes in vitro . Adv Exp Med Biol . 1993;329:275–280
  34. Mohamadzadeh M , Berard F , Essert G , et al.   Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells . J Exp Med . 2001;194:1013–1020
  35. Chomarat P , Dantin C , Bennett L , Banchereau J , Palucka AK . TNF skews monocyte differentiation from macrophages to dendritic cells . J Immunol . 2003;171:2262–2269
  36. Paquette RL , Hsu NC , Kiertscher SM , et al.   Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells . J Leukoc Biol . 1998;64:358–367
  37. Luft T , Pang KC , Thomas E , et al.   Type I INFs enhance the terminal differentiation of dendritic cells . J Immunol . 1998;161:1947–1953
  38. Santini SM , Lapenta C , Logozzi M , et al.   Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice . J Exp Med . 2000;294:1777–1788
  39. Leonard WJ . TSLP (finally in the limelight) . Nat Immunol . 2002;3:605–607
  40. Butterfield LH , Ribas A , Dissette VB , et al.   Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma . Clin Cancer Res . 2003;9:998–1008
  41. Ueda Y , Itoh T , Nukaya I , et al.   Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope (clinical outcomes of 18 patients with metastatic gastrointestinal or lung adenocarcinomas) . Int J Oncol . 2004;24:909–917
  42. Barrou B , Benoit G , Ouldkaci M , et al.   Vaccination of prostatectomized prostate cancer patients in biochemical relapse, with autologous dendritic cells pulsed with recombinant human PSA . Cancer Immunol Immunother . 2004;53:453–460
  43. Hsu FJ , Benike C , Fagnoni F , et al.   Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells . Nat Med . 1996;2:52–58
  44. Timmerman JM , Czerwinski DK , Davis TA , et al.   Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma (clinical and immune responses in 35 patients) . Blood . 2002;99:1517–1526
  45. Reichardt VL , Milazzo C , Brugger W , et al.   Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells . Haematologica . 2003;88:1139–1149
  46. Heiser A , Coleman D , Dannull J , et al.   Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors . J Clin Invest . 2002;109:409–417
  47. Su Z , Dannull J , Yang BK , et al.   Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer . J Immunol . 2005;174:3798–3807
  48. Tucker MJ , Bretscher PA . T cells cooperating in the induction of delayed-type hypersensitivity act via the linked recognition of antigenic determinants . J Exp Med . 1982;155:1037–1049
  49. Bretscher PA . A cascade of T-T interactions, mediated by the linked recognition of antigen, in the induction of T cells able to help delayed-type hypersensitivity responses . J Immunol . 1986;137:3726–3733
  50. Mitchison NA , O’Malley C . Three-cell-type clusters pf T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response . Eur J Immunol . 1987;17:1579–1583
  51. Shirai M , Pendleton CD , Ahlers J , et al.   Helper-cytotoxic T lymphocyte (CTL) determinant linkage required for priming of anti-HIV CD8+ CTL in vivo with peptide vaccine constructs . J Immunol . 1994;152:549–556
  52. Tjoa BA , Simmons SJ , Bowes VA , et al.   Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides . Prostate . 1998;36:39–44
  53. Schuler-Thurner B , Schultz ES , Berger TG , et al.   Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells . J Exp Med . 2002;195:1279–1288
  54. Smithers M , O’Connell K , MacFadyen S , et al.   Clinical response after intradermal immature dendritic cell vaccination in metastatic melanoma is associated with immune response to particulate antigen . Cancer Immunol Immunother . 2003;52:41–52
  55. Svane IM , Pedersen AE , Johnsen HE , et al.   Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer (report from phase I study) . Cancer Immunol Immunother . 2004;53:633–641
  56. Liu KJ , Wang CC , Chen LT , et al.   Generation of carcinoembryonic antigen (CEA)-specific T-cell responses in HLA-A*0201 and HLA-A*2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides . Clin Cancer Res . 2004;10:2645–2651
  57. Geiger JD , Hutchinson RJ , Hohenkirk LF , et al.   Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression . Cancer Res . 2001;61:8513–8519
  58. Chang AE , Redman BG , Whitfield JR , et al.   A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer . Clin Cancer Res . 2002;8:1021–1032
  59. Hernando JJ , Park TW , Kubler K , et al.   Vaccination with autologous tumor antigen-pulsed dendritic cells in advanced gynaecological malignancies (clinical and immunological evaluation of a phase I trial) . Cancer Immunol Immunother . 2002;51:45–52
  60. Oosterwijk-Wakka JC , Tiemessen DM , Bleumer I , et al.   Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2 (a phase I study) . J Immunother . 2002;25:500–508
  61. Iwashita Y , Tahara K , Goto S , et al.   A phase I study of autologous dendritic cell-based immunotherapy for patients with unresectable primary liver cancer . Cancer Immunol Immunother . 2003;52:155–161
  62. Yamanaka R , Abe T , Yajima N , et al.   Vaccination of recurrent glioma patients with tumor lysate-pulsed dendritic cells elicits immune responses (results of a clinical phase I/II trial) . Br J Cancer . 2003;89:1172–1179
  63. Stift A , Friedl P , Dubsky T , et al.   Dendritic cell-base vaccination in solid cancer . J Clin Oncol . 2003;21:135–142
  64. Stift A , Sachet M , Yagubian R , et al.   Dendritic cell vaccination in medullary thyroid carcinoma . Clin Cancer Res . 2004;10:2944–2953
  65. Yu JS , Liu G , Ying H , et al.   Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma . Cancer Res . 2004;64:4973–4979
  66. Pandha HS , John RJ , Hutchinson J , et al.   Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cells (a phase I/II study) . BJU Int . 2004;94:412–418
  67. Vilella R , Benitez D , Mila J , et al.   Pilot study of treatment of biochemotherapy-refractory stage IV melanoma patients with autologous dendritic cells pulsed with a heterologous melanoma cell line lysate . Cancer Immunol Immunother . 2004;53:651–658
  68. Caruso DA , Orme LM , Neale AM , et al.   Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer . Neurooncology . 2004;6:236–246
  69. Caruso DA , Orme LM , Amor GM , et al.   Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma . Cancer . 2005;103:1280–1291
  70. O’Rourke MGE , Johnson M , Lanagan C , et al.   Durable complete clinical responses in a phase I/II trial using an autologous melanoma cell/dendritic cell vaccine . Cancer Immunol Immunother . 2003;52:387–395
  71. Yannelli JR , Sturgill J , Foody T , Hirschowitz E . The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC) . Lung Cancer . 2005;47:337–350
  72. Janetzki S , Palla D , Rosenhauer V , et al.   Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations (a pilot study) . Int J Cancer . 2000;88:232–238
  73. Avigan D , Vasir B , Gong J , et al.   Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses . Clin Cancer Res . 2004;10: 4966-4708
  74. Ossenkoppele GJ , Stam AGM , Westers TM , et al.   Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured leukemic dendritic cells . Leukemia . 2003;17:1424–1426
  75. Choudhury A , Gajewski JL , Liang JC , et al.   Use of leukemic dendritic cells for the generation of antileukemic cellular cytotoxicity against Philadelphia chromosome-positive chronic myelogenous leukemia . Blood . 1997;89:1133–1142
  76. Westers TM , Stam AG , Scheper RJ , et al.   Rapid generation of antigen-presenting cells from leukemic blasts in acute myeloid leukemia . Cancer Immunol Immunother . 2003;52:17–27
  77. Houtenbos I , Westers TM , Stam AG , et al.   Serum-free generation of antigen presenting cells from acute myeloid leukaemic blasts for active specific immunisation . Cancer Immunol Immunother . 2003;52:455–462
  78. Wolkers MC , Brouwenstijn N , Bakker AH , Toebes M , Schumacher TNM . Antigen bias in T-cell cross-priming . Science . 2004;304:1314–1317
  79. Zinkernagel RM . On cross-priming of MHC class I-specific CTL (rule or exception?) . Eur J Immunol . 2002;32:2385–2392
  80. Ochsenbein AF , Sierro S , Odermatt B , et al.   Roles of tumor localization, second signals and cross priming in cytotoxic T-cell induction . Nature . 2001;411:1058–1064
  81. Lee AW , Truong T , Bickham K , et al.   A clinical grade cocktail of cytokines and PGE2 results in uniform maturation of human monocytes-derived dendritic cells (implications for immunotherapy) . Vaccine . 2002;20(suppl 4):A8–A22
  82. Scandella E , Men Y , Gillssen S , Forster R , Groettrup M . Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells . Blood . 2002;100:1354–1361
  83. de Vries IJM , Krooshoop DJEB , Scharenborg NM , et al.   Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state . Cancer Res . 2003;63:12–17
  84. Caux C , Massacrier C , Vanbervliet B , et al.   Activation of human dendritic cells through CD40 cross-linking . J Exp Med . 1994;180:1263–1272
  85. Bedrosian I , Mick R , Xu S , et al.   Intranodal administration of peptide-pulsed mature dendritic cell vaccines results in superior CD8+ T-cell function in melanoma patients . J Clin Oncol . 2003;21:3826–3835
  86. Pasare C , Medzhitov R . Toll-like receptors (linking innate and adaptive immunity) . Microbes Infect . 2004;6:1382–1387
  87. Cisco RM , Abdel-Wahab Z , Dannull J , et al.   Induction of dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4 . J Immunol . 2004;172:7162–7168
  88. Czerniecki BJ , Carter C , Rivoltini L , et al.   Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells . J Immunol . 1997;159:3823–3837
  89. Jenkins MK , Khoruts A , Ingulli E , et al.   In vivo activation of antigen-specific dendritic cells . Annu Rev Immunol . 2001;19:23–45
  90. Matzinger P . Tolerance, danger, and the extended family . Annu Rev Immunol . 1994;12:991–1045
  91. Ridolfi R , Riccobon A , Galassi R , et al.   Evaluation of in vivo labelled dendritic cell migration in cancer patients . J Transl Med . 2004;2:27–37
  92. Hersey P , Menzies SW , Halliday GM , et al.   Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma . Cancer Immunol Immunother . 2004;53:125–134
  93. Lu W , Arraes LC , Ferreira WT , Andrieu JM . Therapeutic dendritic-cell vaccine for chronic HIV-1 infection . Nat Med . 2004;10:1359–1365
  94. Nestle FO , Alijagic S , Gilliet M , et al.   Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells . Nat Med . 1998;4:328–332
  95. Dhodapkar MV , Steinman RM , Sapp M , et al.   Rapid generation of broad T-cell immunity in humans after a single injection of mature dendritic cells . J Clin Invest . 1999;104:173–180
  96. Dhodapkar MV , Steinman RM , Krasovsky J , Munz C , Bhardwaj N . Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells . J Exp Med . 2001;193:233–238
  97. Steinman RM , Hawiger D , Nussenzweig MC . Tolerogenic dendritic cells . Annu Rev Immunol . 2003;21:685–711
  98. Mackensen A , Krause T , Blum U , et al.   Homing of intravenously and intralymphatically injected human dendritic cells generated in vitro from CD34+ hematopoietic progenitor cells . Cancer Immunol Immunother . 1999;48:118–122
  99. Morse MA , Coleman RE , Akabani G , et al.   Migration of human dendritic cells after injection in patients with metastatic malignancies . Cancer Res . 1999;59:56–58
  100. Fong L , Brockstedt D , Benike C , Wu L , Engleman EG . Dendritic cells injected via different routes induce immunity in cancer patients . J Immunol . 2001;166:4254–4259
  101. Schuler G , Steinman RM . Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro . J Exp Med . 1985;161:526–546
  102. Girolomoni G , Simon JC , Bergstresser PR , Cruz PD . Freshly isolated spleen dendritic cells and epidermal Langerhans cells undergo similar phenotypic and functional changes during short-term culture . J Immunol . 1990;145:2820–2826
  103. Maloney DG . Preclinical and phase I and II trials of rituximab . Semin Oncol . 1999;26(5 suppl 14):74–78
  104. Sliwkowski MX , Lofgren JA , Lewis GD , et al.   Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin) . Semin Oncol . 1999;26(4 suppl 12):60–70
  105. Dannull J , Nair S , Su Z , et al.   Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand . Blood . 2005;105:3206–3213
  106. Ribas A , Butterfield LH , Amarnani SN , et al.   CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells . Cancer Res . 2001;61:8787–8793
  107. Demuth T , Berens ME . Molecular mechanisms of glioma cell migration and invasion . J Neurooncol . 2004;70:217–228
  108. Ridgway D . The first 1000 dendritic cell vaccinees . Cancer Invest . 2003;21:873–886
  109. Janeway CA , Travers P , Hunt S , Walport M . Immunobiology (The Immune System in Health and Disease) . 3rd ed.. New York: Garland Publishing Inc; 1997;
  110. Bennett SRM , Carbone FR , Karamalis F , Miller JFAP , Heath WR . Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help . J Exp Med . 1997;186:65–70
  111. Bennett SRM , Carbone FR , Karamalis F , et al.   Help for cytotoxic-T-cell responses is mediated by CD40 signalling . Nature . 1998;393:478–480
  112. Schoenberger SP , Toes REM , Van der Voort EIH , Offringa R , Melief CJM . T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions . Nature . 1998;393:480–483
  113. Van Mierlo GJD , Boonman ZFHM , Dumortier HMH , et al.   Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication . J. Immunol . 2004;173:6753–6759
  114. Behrens G , Li M , Smith CM , et al.   Helper T cells, dendritic cells and CTL immunity . Immunol Cell Biol . 2004;82:84–90
  115. Rocha B , Tanchot C . Towards a cellular definition of CD8+ T-cell memory (the role of CD4+ T-cell help in CD8+ T-cell responses) . Curr Opin Immunol . 2004;16:259–263
  116. Bourgeois C , Rocha B , Tanchot C . A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory . Science . 2002;297:2060–2063
  117. Tham EL , Shrikant P , Mescher MF . Activation-induced nonresponsiveness (a Th-dependent regulatory checkpoint in the CTL response) . J Immunol . 2002;168:1190–1197
  118. Macian F , Im SH , Garcia-Cozar FJ , Rao A . T-cell anergy . Curr Opin Immunol . 2004;16:209–216
  119. Sprent J , Kishimoto H . The thymus and negative selection . Immunol Rev . 2002;185:126–135
  120. Decker WK , Xing D , Li S , et al.   Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances T-cell responses in vitro . Blood . 2004;104:693a
  121. Lim SH , Baily-Wood R . Idiotype protein-pulsed dendritic cell vaccination in multiple myeloma . Int J Cancer . 1999;83:215–222
  122. Titzer S , Christensen O , Manzke O , et al.   Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells (immunological and clinical aspects) . Br J Haematol . 2000;108:805–816
  123. Maecker HT , Auffermann-Gretzinger S , Nomura LE , et al.   Detection of CD4 T-cell responses to a tumor vaccine by cytokine flow cytometry . Clin Cancer Res . 2001;7(suppl 3):902s–908s

PII: S1083-8791(05)00630-0

doi: 10.1016/j.bbmt.2005.09.003

Biology of Blood and Marrow Transplantation
Volume 12, Issue 2 , Pages 113-125 , February 2006

Article Tools

* Image Usage & Resolution